Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202

Heather J. Ribaudo, Eric S. Daar, Camlin Tierney, Gene D. Morse, Katie Mollan, Paul E. Sax, Margaret A Fischl, Ann C. Collier, David W. Haas

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8% of whites, 24% of blacks, and 18% of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P =. 005) but not among white or black participants (P =. 79 and P =. 46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%-52%).

Original languageEnglish
Pages (from-to)420-425
Number of pages6
JournalJournal of Infectious Diseases
Volume207
Issue number3
DOIs
StatePublished - Feb 1 2013

Fingerprint

Ritonavir
Acquired Immunodeficiency Syndrome
Clinical Trials
Hispanic Americans
Tenofovir
efavirenz
Hyperbilirubinemia
Bilirubin
Atazanavir Sulfate
HIV-1
Confidence Intervals

Keywords

  • atazanavir
  • Gilbert syndrome
  • HIV therapy
  • pharmacogenetics
  • UGT1A1

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202. / Ribaudo, Heather J.; Daar, Eric S.; Tierney, Camlin; Morse, Gene D.; Mollan, Katie; Sax, Paul E.; Fischl, Margaret A; Collier, Ann C.; Haas, David W.

In: Journal of Infectious Diseases, Vol. 207, No. 3, 01.02.2013, p. 420-425.

Research output: Contribution to journalArticle

Ribaudo, Heather J. ; Daar, Eric S. ; Tierney, Camlin ; Morse, Gene D. ; Mollan, Katie ; Sax, Paul E. ; Fischl, Margaret A ; Collier, Ann C. ; Haas, David W. / Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202. In: Journal of Infectious Diseases. 2013 ; Vol. 207, No. 3. pp. 420-425.
@article{6fd82b3f1a8146f1a3dedf86d07e47fd,
title = "Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202",
abstract = "The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8{\%} of whites, 24{\%} of blacks, and 18{\%} of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P =. 005) but not among white or black participants (P =. 79 and P =. 46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32{\%} (95{\%} confidence interval, 16{\%}-52{\%}).",
keywords = "atazanavir, Gilbert syndrome, HIV therapy, pharmacogenetics, UGT1A1",
author = "Ribaudo, {Heather J.} and Daar, {Eric S.} and Camlin Tierney and Morse, {Gene D.} and Katie Mollan and Sax, {Paul E.} and Fischl, {Margaret A} and Collier, {Ann C.} and Haas, {David W.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1093/infdis/jis690",
language = "English",
volume = "207",
pages = "420--425",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202

AU - Ribaudo, Heather J.

AU - Daar, Eric S.

AU - Tierney, Camlin

AU - Morse, Gene D.

AU - Mollan, Katie

AU - Sax, Paul E.

AU - Fischl, Margaret A

AU - Collier, Ann C.

AU - Haas, David W.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8% of whites, 24% of blacks, and 18% of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P =. 005) but not among white or black participants (P =. 79 and P =. 46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%-52%).

AB - The UGT1A1*28 variant has been associated with hyperbilirubinemia and atazanavir discontinuation. Protocol A5202 randomly assigned human immunodeficiency virus type 1 (HIV-1)-infected patients to receive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lamivudine. A total of 646 atazanavir/r recipients were evaluable for UGT1A1. Homozygosity for *28/*28 was present in 8% of whites, 24% of blacks, and 18% of Hispanics and was associated with increased bilirubin concentrations. There was an association between *28/*28 and increased atazanavir/r discontinuation among Hispanic participants (P =. 005) but not among white or black participants (P =. 79 and P =. 46, respectively). The positive predictive value of 28*/28* for atazanavir/r discontinuation among Hispanic participants was only 32% (95% confidence interval, 16%-52%).

KW - atazanavir

KW - Gilbert syndrome

KW - HIV therapy

KW - pharmacogenetics

KW - UGT1A1

UR - http://www.scopus.com/inward/record.url?scp=84872006714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872006714&partnerID=8YFLogxK

U2 - 10.1093/infdis/jis690

DO - 10.1093/infdis/jis690

M3 - Article

VL - 207

SP - 420

EP - 425

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -